drugset / Trial / NCT05209295
A Study to Evaluate CC-486/Onureg in Participants With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Participants With Myeloid Malignancies
Non-randomizedParallel-groupOpen-labelBasic science
Summary
The purpose of this study is to evaluate the effect of moderate or severe liver impairment on the drug levels of oral azacitidine and the safety and tolerability of oral azacitidine in participants with myeloid malignancies.
Timeline
- Start
- 2024-07-12
- Primary completion
- 2025-04-20
- Completion
- 2025-04-20
Outcome
Outcome not reported
Stopped (Enrollment): “Insufficient Enrollment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | — | Oral |